10 August, 2018
Skadden advised BeiGene Ltd. (China and Massachusetts, USA), a biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, on its approximately US$ 903 million initial public offering on the Hong Kong Stock Exchange.
This is Hong Kong's largest ever biotechnology IPO to date, and is also the first ever dual primary listing of a Nasdaq-listed biotechnology company. Trading in the shares commenced on 8 August 2018.
The Skadden team was led by partnersChristopher W. Betts andAndrea L. Nicolaswith Counsel Benjamin K. Marsh, associates Deni Li, Allan Wan, Daniel A. Ursomanno Jr., Ming Kong, Sophia Tong and trainee solicitorNicole Yuen. Partner Pamela Lawrence Endrenyand associate Jennifer L. Sabin assisted on tax matters. The attorneys are based in Hong Kong, Beijing, Shanghai and New York.
